SJP-002X

SJP-002X is an oral prescription (Rx) small molecule combination therapeutic candidate under development by Sen-Jam Pharmaceutical for metabolic health indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), and metabolic recovery. Developed using Sen-Jam's proprietary AI-driven Inflammation Atlas and Pleiotropic Anti-Inflammatory Remedies (PAIR) technology, SJP-002X is designed to target systemic and tissue-specific inflammation at its source. The therapeutic utilizes a dual-action mechanism that combines cyclooxygenase (COX) inhibition with mast cell stabilization to interrupt lipid-driven inflammatory cascades, reduce lipotoxicity, and mitigate neuroinflammation that drives metabolic dysfunction.